Wegovy at ObesityWeek 2024 (Credit: Kyle LaHucik for Endpoints News)
November 3, 2024 03:30 PM ESTUpdated November 4, 06:18 AM
Pharma

No­vo adds to We­govy’s car­dio strength with hos­pi­tal ad­mis­sions analy­sis

Kyle LaHucik

Senior Reporter

SAN AN­TO­NIO — No­vo Nordisk’s wild­ly pop­u­lar an­ti-obe­si­ty drug We­govy helped heart dis­ease pa­tients end up in the hos­pi­tal less of­ten and stay there for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times